Johnson & Johnson $JNJ Shares Sold by Epoch Investment Partners Inc.

Key Points

• Epoch Investment Partners Inc. has reduced its stake in Johnson & Johnson by 1.1%, bringing its total holdings to 471,543 shares worth approximately $78.2 million.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, with a yield of 2.9% and a payout ratio of 55.61%.
• Despite recent changes in institutional holdings, analysts maintain a consensus rating of "Moderate Buy" for Johnson & Johnson, with a target price around $176.29.

Epoch Investment Partners Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 471,543 shares of the company's stock after selling 5,337 shares during the period. Epoch Investment Partners Inc.'s holdings in Johnson & Johnson were worth $78,201,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Highline Wealth Partners LLC boosted its holdings in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter valued at about $47,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the 1st quarter valued at approximately $49,000. Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $52,000. Finally, Capital A Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $50,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. UBS Group upped their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Finally, Bank of America increased their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Price Performance

JNJ stock traded down $1.29 on Thursday, reaching $175.50. The company had a trading volume of 6,423,524 shares, compared to its average volume of 8,630,407. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company's fifty day moving average is $164.95 and its 200 day moving average is $159.72. The company has a market cap of $422.67 billion, a P/E ratio of 17.68, a PEG ratio of 2.25 and a beta of 0.41. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.